Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions.

Mainz Biomed (MYNZ) announced it has entered into a License and Option Agreement with Liquid Biosciences to access a portfolio of novel mRNA ...

With these developments, Mainz Biomed is now fully compliant with all Nasdaq continued listing standards and will maintain its listing and trading on the Nasdaq Capital Market. Mainz Biomed ...

Mainz Biomed (MYNZ) supports Colorectal Cancer Awareness Month in March. Detecting colorectal cancer in its early stages significantly improves ...

Bayern Munich is once again making waves in the transfer market as they consider Mainz's 24-year-old forward, Burkhardt, as a potential backup for Harry Kane. This article will delve into Bayern’s ...

BERKELEY, Calif. and MAINZ, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular ...

Mainz Biomed B.V. has entered into a supplemental ... which aims to pave the way for entry into the U.S. market. Management believes 2025 will be a ...